Media Doctor Canada
Follow us on Twitter








"Thalidomide approved for bone-marrow cancer"


Source: CTV.CA

Published: 26 May 2022

Category: Pharmaceutical

Rating: (1½ stars)

what they said (Hover the mouse cursor over underlined words for more info)

Associated Press
WASHINGTON -- Thalidomide received federal approval Thursday for treatment of bone-marrow cancer, marking the further rehabilitation of a drug originally banned more than 40 years ago after it caused thousands of birth defects.
The Food and Drug Administration approved the drug for the treatment of newly diagnosed multiple myeloma, agency spokeswoman Laura Alvey said.
Multiple myeloma refers to cancers that affect cells in the bone marrow that are key to fighting infection....

The original article can found in the Media Doctor archives.

how did it rate? (more information)

Criteria Rating
Total Score 3 of 11
Availability of Treatment Not Satisfactory (?)
Novelty of Treatment Satisfactory (?)
Disease Mongering Satisfactory (?)
Treatment Options Not Satisfactory (?)
Costs of Treatment Not Satisfactory (?)
Evidence Not Satisfactory (?)
Quantification of Benefits of Treatment Not Satisfactory (?)
Harms of Treatment Satisfactory (?)
Sources of Information Not Satisfactory (?)
Relies on Press Release Not Satisfactory (?)
Quantification of Harms of Treatment Not Satisfactory (?)

what we said (Hover the mouse cursor over underlined words for more info)

This story contains an inaccurate description of Thalidomide's side effects and harms when prescribed for this indication, particularly regarding the potential of thromboembolic events. Among other important information, the author of this story forgot to mention the nature of the studies that gave thalidomide its approval (non-controlled studies) for this indication

Actually the press release is much more informative than the story. The story appears to be a simple rewrite of the press release, although it does not use direct quotes. There seems to be no evidence that other sources of information have been used.

Thalidomide has been in use at the BC Cancer Agency since 1991 for the treatment of multiple myeloma refractory to standard treatments i.e. melphalan, prednisone, pamidronate, dexamethasone, and more recently bortezomib. Drowsiness, constipation, and peripheral nerve damage (sometimes permanent) are the most common side effects. Birth defects, while serious, are not generally an issue as multiple myeloma is not by and large a disease of reproductive-age women

public forum

There are currently no comments on this article.

voice your opinion in the forum

  • All comments and feedback submitted to Media Doctor are subject to editorial approval before being made viewable by the public. It may take up to a week for your comments to be approved. Additionally, no response will be given to questions posed in public comments. Media Doctor does not provide medical advice, or answers to medical questions posed by the public.
  • If you provide your email address it will not be displayed to the general public.
  • Comments may be edited by Media Doctor to remove defamatory or sensitive statements, and brand names.
  • Required fields are marked with an asterisk (*).
Name: *
Comments: *
Copyright © Media Doctor Canada